Japan moves to tighten oversight of private regenerative-medicine clinics after patient deaths
Japan's health ministry is weighing stricter regulations for regenerative-medicine treatments after several patient deaths and safety breaches at private clinics.
Regenerative-medicine services, including stem-cell injections and emerging exosome-based liquids, are expanding in Japanese private clinics and are marketed for anti-aging, orthopedic, dental and cancer applications. Under the Health, Labour and Welfare Ministry's safety law, treatments are divided into three risk categories, but recent serious adverse events—two 2024 hospitalisations from sepsis after immune-cell infusions and deaths in 2025-26 following fat-derived cell therapies—have raised safety concerns.
The ministry responded with emergency orders to suspend unsafe practices, yet some clinics have formally closed only to continue elsewhere, and review committees may suffer conflicts of interest. In July, a health-ministry working group warned that the pre-approval process risks becoming a formality and called for clearer assessment of non-research regenerative products, better patient disclosures, and improved reporting of adverse effects. The group aims to produce a report by the end of one outlet fiscal year through March, recommending that exosome therapies be brought under the existing regenerative-medicine safety law.
Why it matters
Regulatory gaps could expose patients to unsafe stem-cell and exosome treatments as the market expands.
In this story
